| Focus: | To catalyze and support discovery, development, networking, capacity building, commercialization and knowledge translation to reduce the burden of allergic and related immune diseases. |
| Funding: | $37,842,500 for entire funding period |
| Strength: | 186 researchers and 154 highly qualified personnel |
| Partnership Power: | 210 industry, public service and academic partners |
| Scientific Director and CEO: | Dr. Judah Denburg |
| Web site: |